FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted ...

Trading will remain halted until Robot Consulting Co., Ltd. has fully satisfied Nasdaq’s request for additional information. For news and additional information about the company, please contact the ...

ORR and preliminary duration of treatment data for the Phase 2 trial of silevertinib in 1L patients with non-classical EGFRm NSCLC on track for ...

Achieved record-high quarterly revenues, Adjusted EBITDA 1 and Adjusted EBITDA per share 1 since inception Increased 2025 financial guidance ...

According to the USGS, "The development of awaruite deposits in other parts of Canada may help alleviate any prolonged ...

Raises Revenue Guidance, Completes Medsphere Acquisition and Accelerates AI InitiativeSOMERSET, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ...

PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth ...

Total Revenue Increased 2% Sequentially Delivered $0.35 AFFO Per Share Reiterated 2025 Full-Year Outlook ATLANTA, GA, Nov. 06, 2025 (GLOBE ...

End of Period Subscribers of 3.0 million, including Clinical Subscribers of 124 thousand Total Revenues of $172 million; Clinical Subscription ...

STAFFORD, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Microvast Holdings, Inc. (NASDAQ: MVST), (“Microvast” or the “Company”), a global leader in advanced battery technologies, will issue a press release ...

TREOS Bio today announced the publication in Journal of Clinical Oncology - Oncology Advances of results from OBERTO-201 (NCT05130060), a Phase 1b study evaluating PolyPEPI1018, an off-the-shelf multi ...

About ATV Technologies: ATV is a leading contract development manufacturing organization specializing in advanced fermentation processes for a range of applications across the biotechnology, DSP and ...